Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526208 · ClinicalTrials.gov registry record · Phase 2
Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults
A Phase 2 study, sponsored by Southwest Autism Research & Resource Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT06526208 is a Phase 2 study that is actively recruiting participants, run by Southwest Autism Research & Resource Center. The registered enrollment target is 108 participants.
The verdict
NCT06526208, a Phase 2 study, is actively recruiting participants, sponsored by Southwest Autism Research & Resource Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are: Will a marijuana-based drug help anxiety in autistic adults? Anxiety can make socializing and working more difficult for people. Researchers will compare a marijuana based drug (that is mostly CBD with a small amount of THC) to a placebo (a look-alike substance that contains no drug) to see if the drug makes symptoms of anxiety better. Participants will take the drug (or a placebo) every day for 8 weeks and keep a diary to record the time they took the drug, and their feelings each day. The drug is taken orally in drops once or twice a day. The study staff will speak to the participants weekly either over the phone or in the clinic. Clinic visits once every 2 weeks for checkups and tests. The researchers will make sure participants are healthy and see if there are any changes in anxiety.
Interventions
- OTHER Placebo
- DRUG MB-IMP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526208
The ClinicalTrials.gov registry entry for NCT06526208 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southwest Autism Research & Resource Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06526208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06526208 about?
NCT06526208 is a clinical study titled "Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults". The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are: Will a marijuana-based drug help anxiety in autistic adults? Anxiety can make socializing and working more diff...
What is the current status of trial NCT06526208?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2025-05-28. Estimated completion is 2027-09-30.
What interventions are being tested in trial NCT06526208?
The interventions under investigation include: Placebo (OTHER), MB-IMP (DRUG).
Who is sponsoring clinical trial NCT06526208?
This trial is sponsored by Southwest Autism Research & Resource Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.